Maaike Sohne

Nieuwegein, UT, NL 
Nieuwegein, UT, NL 

Overview

Maaike Sohne practices practicing medicine in Nieuwegein, Netherlands.

Her clinical expertise encompasses Multiple Myeloma, Ecthyma, Hairy Cell Leukemia (HCL), and Myelodysplastic Syndrome (MDS).

She is actively involved in clinical research, co-authoring 14 peer reviewed articles and participating in 1 clinical trial.

Gender

Female

Locations

Nieuwegein, UT, Netherlands
Other Locations
Flevoziekenhuis
Almere Stad, FL, Netherlands
St Antonius Hospital
Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Daratumumab, Bortezomib, Dexamethasone
Study Phase: Phase 3

14 Total Publications

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 18, 2025

Frequently Asked Questions about Maaike Sohne

Is Maaike Sohne a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Maaike Sohne is classified as an Experienced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Maaike Sohne participate in research or clinical trials?

Yes. Maaike Sohne has published 14 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Maaike Sohne's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Sohne's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile